Table III.
bDLE affects chemokine production in K562 cells.
| Chemokine production, pg/ml | |||
|---|---|---|---|
| Treatment | CCL2/MCP-1 | CCL5/RANTES | CXCL8/IL-8 |
| Untreated cells | 25.07 | 0.7 | 17.84 |
| bDLE 0.07 U/ml | 70.42 | 4.17 | 47.35 |
| bDLE 0.14 U/ml | 66.07 | 2.76 | 46.29 |
| bDLE 0.21 U/ml | 74.02 | 0.7 | 19.44 |
| bDLE 0.28 U/ml | 115.81 | 0 | 20.05 |
| bDLE 0.35 U/ml | 164.15 | 0.31 | 28.23 |
| PMA | 9994.53 | 143.78 | 12105.23 |
| DMSO | 10.22 | 0 | 2.58 |
K562 cells were treated with bDLE, PMA or DMSO. Following 96 h of incubation the supernatants were harvested and prepared according to the manufacturer's protocol (Cytometric Bead Array Human Inflammatory Cytokines kit; BD Biosciences). A total of 10,000 events were analyzed by flow cytometry. bDLE, bovine dialyzable leukocyte extract; PMA, phorbol myristate acetate; DMSO, dimethyl sulfoxide; CCL, chemokine (C-C motif) ligand; RANTES, regulated on activation, normal T cell expressed and secreted; CXCL, chemokine (C-X-C motif) ligand; IL, interleukin.